YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Nigris, Filomena de ^a,e   Zanella, Licciana ^b   Cacciatore, Francesco ^c   Chiara, Anna De ^d   Fazioli, Flavio ^d   Chiappetta, Gennaro ^d   Apice, Gaetano ^d   Infante, Teresa ^e   Monaco, Mario ^d   Rossiello, Raffaele ^a   Rosa, Gaetano De ^f   Alberghini, Marco ^b   Napoli, Claudio ^a,e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c IRCCS   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e IRCCS SDN   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; TRANSCRIPTION FACTOR YY1; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; TREATMENT DURATION; ANALYSIS OF VARIANCE; BONE TUMOR; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; ANALYSIS OF VARIANCE; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; OSTEOSARCOMA; PROGNOSIS; PROSPECTIVE STUDIES; YY1 TRANSCRIPTION FACTOR;

EID: 80055115344     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-472     Document Type: Article

References (35)

1. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy 15-year experience in 789 patients treated at a single institution. Cancer 2006, 106:1154-1161. 10.1002/cncr.21724, 16421923.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790. 10.1200/JCO.20.3.776, 11821461.
3. Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, Pignotti E, Bacci G. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol 2010, 21:1366-1373. 10.1093/annonc/mdp502, 19889609.
4. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006, 32:423-436. 10.1016/j.ctrv.2006.05.005, 16860938.
5. Kim MS, Lee SY, Lee TR, Cho WH, Song W, Koh JS, Lee JA, Yoo JY, Jeon DG. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol 2009, 20:955-960. 10.1093/annonc/mdn723, 19153123.
6. Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep 2002, 1:171-175.
7. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003, 3:536-542.
8. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005, 11:2561-2567. 10.1158/1078-0432.CCR-04-1089, 15814634.
9. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 2006, 3:95-100.
10. Kim C, Shin E, Hong S. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 2009, 41:138-144. 10.4143/crt.2009.41.3.138, 2757658, 19809563.
11. Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 2010, 10:202-211. 10.1186/1471-2407-10-202, 2875220, 20465837.
12. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008, 134:281-297. 10.1007/s00432-007-0330-x, 17965883.
13. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006, 25:1125-1142. 10.1038/sj.onc.1209080, 16314846.
14. Zaravinos A, Spandidos DA. Yin Yang expression in human tumors. Cell Cycle 2010, 9:512-522. 10.4161/cc.9.3.10588, 20081375.
15. Rizkallah R, Alexander KE, Kassardjian A, Lüscher B, Hurt MM. The transcription factor YY1 is a substrate for Polo-like kinase 1 at the G2/M transition of the cell cycle. PLOS One 2011, 6:e15928. 10.1371/journal.pone.0015928, 3017090, 21253604.
16. de Nigris F, Botti C, de Chiara A, Rossiello R, Apice G, Fazioli F, Fiorito C, Sica V, Napoli C. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer 2006, 42:2420-2424. 10.1016/j.ejca.2006.06.008, 16962318.
17. de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells. Oncogene 2007, 26:382-394. 10.1038/sj.onc.1209804, 16878156.
18. de Nigris F, Rossiello R, Schiano C, Arra C, Williams-Ignarro S, Barbieri A, Lanza A, Balestrieri A, Giuliano MT, Ignarro LJ, Napoli C. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res 2008, 68:1797-1808. 10.1158/0008-5472.CAN-07-5582, 18339860.
19. de Nigris F, Crudele V, Giovane A, Casamassimi A, Giordano A, Garban HJ, Cacciatore F, Pentimalli F, Marquez-Garban DC, Petrillo A, Cito L, Sommese L, Fiore A, Petrillo M, Siani A, Barbieri A, Arra C, Rengo F, Hayashi T, Al-Omran M, Ignarro LJ, Napoli C. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci USA 2010, 107:14484-14489. 10.1073/pnas.1008256107, 2922579, 20660740.
20. Napoli C, Giordano A, Casamassimi A, Pentimalli F, Ignarro LJ, de Nigris F. Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int J Cancer 2011, 120:1505-1508.
21. Marcove RC, Heelan RT, Huvos AG, Healey J, Lindeque BG. Osteoid osteoma. Diagnosis, localization, and treatment. Clin Orthop Relat Res 1991, 267:197-201.
22. Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995, 333:1380-1385. 10.1056/NEJM199511233332103, 7477118.
23. Rasalkar DD, Chu WC, Lee V, Paunipagar BK, Cheng FW, Li CK. Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr Radiol 2011, 41:227-236. 10.1007/s00247-010-1809-1, 20814672.
24. Davicioni E, Wai DH, Anderson MJ. Diagnostic and prognostic sarcoma signatures. Mol Diagn Ther 2008, 12:359-374.
25. Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta 2009, 1796:176-193. 2752479, 19406210.
26. Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 2005, 27:131-141.
27. Chinnapan D, Xiao D, Ratnasari A, Andry C, King TC, Weber HC. Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol 2009, 34:1417-1423.
28. Huerta-Yepez S, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol 2006, 120:297-309. 10.1016/j.clim.2006.03.015, 16784892.
29. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008, 180:6199-6210.
30. Oda Y, Tateishi N, matono H, matsuura S, Yamamaoto H, Tamiya S, Yokiyama R, matsuda S, Iwamoto Y, Tsuneyoshi M. Chemokine receptor CXCR4 expression is correlated to VEGF expression and poor survival in soft tissue sarcoma. Int J Cancer 2009, 124:1852-1859. 10.1002/ijc.24128, 19107931.
31. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent J, Araujo D, Chen K, Zhang W, Matsumura N. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 2011,
32. Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK. Yin Yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 2009, 7:210-220. 10.1158/1541-7786.MCR-08-0255, 2675878, 19208743.
33. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer 2008, 8:394. 10.1186/1471-2407-8-394, 2642844, 19116006.
34. Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma a pilot study. Clin Orthop Relat Res 2009, 467:2932-2938. 10.1007/s11999-009-0814-x, 2758970, 19326179.
35. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 2009, 26:1005-1012. 10.1007/s10585-009-9290-7, 19802733.